Engflag

U-Closone

Quick links to important sections

U-Closone

U-Closone_EN

Method of action: Anti-Inflammatory, Corticosteroids, Dermatological Preparations, Very Strong

Treatment option: Plaque Psoriasis, Lupus, Dermatitis, Discoid Lupus Erythematosus, Empeines, Perioral Dermatitis, Psoriasis, Blackheads, Eczema

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of U-Closone

Quick Facts about U-Closone

Property Description
Active Ingredient Clobetasone Butyrate
Pharmacological Class Topical Corticosteroid (Moderately Potent)
Form Cream or Ointment
Rx/OTC Status Prescription Only (Rx)
Common Use Managing inflammatory skin flare-ups

U-Closone: Understanding Its Identity and Purpose

U-Closone is a prescription-only topical medication, most often supplied as a cream or ointment for application directly to the skin. It is based on the active component Clobetasone Butyrate, which is the International Nonproprietary Name (INN) for this synthetic steroid. Its fundamental purpose is to provide rapid relief from the common inflammatory symptoms of skin conditions, specifically targeting redness, swelling, and itching.

The brand U-Closone is typically reserved for short-term use to bring acute inflammatory flare-ups under control, such as cases of severe contact dermatitis. This medicine is solely for external dermatological use and is distinct from medications taken orally or those used to treat infections.

What is the Main Component of U-Closone?

The active ingredient, Clobetasone Butyrate, is classified as a synthetic corticosteroid. This component is recognized for possessing a relatively high level of topical effectiveness combined with a low potential for systemic activity. This characteristic differentiation means the drug is designed to work strongly where applied on the skin while minimizing absorption into the wider bloodstream.

Clobetasone Butyrate is categorized as a Moderately Potent (Group II) topical corticosteroid. The product's formulation, whether as a cream or an ointment, includes various inactive ingredients that act as a vehicle to ensure the effective, localized delivery of the active drug through the skin's surface.

What Health Issues is U-Closone Used For?

U-Closone is indicated for the symptomatic management of various inflammatory and pruritic (itchy) dermatoses that respond well to steroid therapy. It is frequently prescribed to help manage flare-ups of chronic conditions like eczema and various forms of dermatitis. The therapeutic goal is to suppress the localized immune and inflammatory processes that cause the skin discomfort.

The effectiveness of Clobetasone Butyrate in reducing key inflammatory symptoms has been consistently supported by pharmacological evidence, confirming its role in improving the comfort and appearance of affected skin.

What side effects are possible with U-Closone?

Possible Side Effects and Safety Information

U-Closone (clobetasone butyrate) is a potent topical corticosteroid, and its safety profile, as documented in regulatory sources, is structured by both common localized reactions and potential systemic effects linked to absorption.

Adverse Reactions

Most reactions are common and are limited to the site of application. These local effects can include a burning or stinging sensation, irritation, dryness, and atrophy (skin thinning). Certain localized reactions, such as the development of stretch marks (striae) and the widening of small blood vessels (telangiectasia), are also documented.

Very rare and serious adverse reactions are associated with the systemic absorption of the medicine and primarily affect the endocrine system. These include the suppression of the hypothalamic-pituitary-adrenal (HPA) axis and features of Cushing's syndrome, particularly with intensive or prolonged use. Other systemic concerns include secondary infections at the application site and, rarely, eye disorders like cataract and glaucoma if the medicine enters the eye.

Safety Considerations and Restrictions

Risk of systemic absorption and associated effects is increased by:

  • Prolonged duration of use.
  • Application to large surface areas.
  • Use under occlusive dressings (a baby's diaper may act as an occlusive dressing).
  • Use on areas with thin skin, such as the face.

Population-Specific Warnings:

  • Children are documented as being at a higher risk of systemic side effects, including HPA axis suppression and growth retardation, due to a larger skin surface area relative to body weight. Use in this population is therefore subject to strict caution and is typically limited to short durations.
  • Pregnancy and Breastfeeding safety has not been fully established, and its use must be weighed against the potential risks of systemic absorption.

Contraindications in regulatory documents include untreated infections of bacterial, viral (e.g., herpes simplex), fungal, or parasitic origin, as well as skin conditions such as rosacea, acne vulgaris, and perioral dermatitis. The medicine is not recommended for use on the eyelids.

Overdose and Emergency Response

Overdose and When to Seek Help

The primary concern for overdose with U-Closone (clobetasone butyrate) is not a single acute event but rather the risk of systemic toxicity following prolonged or excessive application to the skin.

Overuse or application over large surface areas, especially with occlusive dressings, may result in increased systemic absorption of the topical corticosteroid. This can lead to officially documented endocrine disturbances:

  • Hypercortisolism (Cushing's syndrome): Manifestations can include weight gain, 'moon face' or rounding of the face, and central obesity.
  • Hypothalamic-Pituitary-Adrenal (HPA) axis suppression: This is a serious risk where the body's natural production of cortisol is suppressed, potentially leading to glucocorticosteroid insufficiency, especially upon abrupt withdrawal.

Population-Specific Overdose Risks:

Children and infants are at a greater risk for systemic toxicity and HPA axis suppression than adults due to their larger skin surface area-to-body mass ratio. Systemic effects in children may include delayed weight gain or growth retardation.

Emergency Actions and Seeking Medical Help:

Immediate medical assistance should be sought in two primary situations as specified in regulatory information:

  1. If the product is accidentally ingested (swallowed).
  2. If you observe signs of systemic toxicity (such as Cushingoid features or extreme fatigue) following excessive or prolonged topical use.

In cases where HPA axis suppression is observed, the official guidance is to attempt to gradually withdraw the drug under the supervision of a healthcare professional. Abrupt cessation may result in glucocorticosteroid insufficiency.

Therapeutic Uses of U-Closone

What U-Closone Treats: Main Uses and Benefits

U-Closone is commonly used in therapeutic domains involving inflammatory skin conditions. It is relevant for managing conditions characterized by periods of heightened symptoms, such as flare-ups of chronic disorders like eczema, various forms of dermatitis, and allergic contact dermatitis. It is applied when appropriate for the management of symptoms related to physical discomfort.

This medication is applied across domains where additional symptomatic support is needed. It is often applied in addressing symptom clusters that may become intense or disruptive, specifically redness (erythema), swelling, and persistent itching (pruritus). It is generally relevant for managing symptoms that interfere with daily comfort. In situations where symptoms become more noticeable, this medication contributes to improved day-to-day comfort. U-Closone is commonly used when short-term symptomatic assistance is needed during phases of increased distress, supporting patients during episodes of heightened discomfort.

Quick Fact: Relief for Acute Inflammation

Therapeutic Focus Symptoms Addressed
Use Context Short-term management of acute flare-ups.
Symptoms Addressed Redness, swelling, and intense itching (pruritus).
Patient Benefit Contributes to easing the overall symptom load.

Eligibility and Restrictions for Use

This information is based on the official regulatory documentation for the drug Clobetasone Butyrate 0.05%, which is the standardized generic name for U-Closone in this context.

Populations That Must Not Use U-Closone

The medicine is formally contraindicated and must not be used by individuals who meet the following criteria, as stated in authoritative regulatory labels:

  • Hypersensitivity: Known allergy or history of reaction to the active substance (clobetasone butyrate) or any other ingredients in the formulation.
  • Specific Skin Conditions: Individuals with rosacea, acne vulgaris, or perioral dermatitis (a rash around the mouth).
  • Infections: Patients with untreated cutaneous infections, including viral (e.g., cold sores, chickenpox), fungal, or bacterial infections at the treatment site.

Populations with Restricted or Not Recommended Use

Use is strongly restricted for certain populations or specific areas of the body due to increased risk of systemic absorption and side effects:

  • Age Restriction: Use in children under 12 years of age is not recommended as safety and effectiveness have not been adequately established, and children are more susceptible to systemic effects. Treatment for children over 12 is generally limited in duration.
  • Application Site Restriction: The product must not be used on the face, groin, or axillae (armpits), and use should be avoided if skin atrophy (thinning) is already present at the treatment site.
  • Pregnancy and Lactation: Use during pregnancy and breastfeeding should only be considered if the potential benefit to the mother is determined to outweigh the potential risk to the fetus or infant. Application on the breast area during lactation is typically discouraged.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for U-Closone (clobetasol propionate) is primarily defined by the potential for increased systemic exposure and subsequent systemic effects when combined with certain other medicines.

Key Interaction Categories

Mechanism / Substance Class Interacting Medicines Explicitly Listed
Inhibitors of CYP3A4 Enzymes Itraconazole, Ritonavir
Other Agents with Potential PD Effects Aldesleukin, Ceritinib, Corticorelin, Deferasirox, Hyaluronidase

Interaction-Related Constraints and Practical Implications

Concomitant use with strong inhibitors of the CYP3A4 enzyme may significantly raise the concentration of U-Closone in the bloodstream, increasing the risk of systemic side effects. Healthcare providers should assess the need for such combinations and monitor patients for signs of increased systemic absorption, particularly during prolonged use or application over a large body surface area.

Regulatory documents also detail several pharmacodynamic (PD) interactions where U-Closone may either diminish the therapeutic effect of a co-administered medicine (e.g., Corticorelin and Hyaluronidase) or enhance the adverse effects of another (e.g., the hyperglycemic effect of Ceritinib). Therefore, the combination with agents such as Aldesleukin, Ceritinib, Corticorelin, Deferasirox, and Hyaluronidase requires careful clinical consideration to manage the therapeutic outcome and potential for enhanced toxicity.

Mechanism of Action

How U-Closone Works

U-Closone acts through a coordinated genomic mechanism to dampen the biological processes that sustain inflammatory signaling at the cellular level. Its core action involves three interconnected mechanistic domains: receptor binding, enzymatic blockade, and localized vascular modulation.

Targeting the Intracellular Glucocorticoid Receptor

The mechanism initiates when Clobetasone Butyrate binds to the Cytoplasmic Glucocorticoid Receptor (GR) inside skin cells, acting as an agonist. This binding enables the drug-receptor complex to enter the nucleus and directly modulate gene transcription, specifically by increasing the production of anti-inflammatory proteins and decreasing the synthesis of pro-inflammatory messengers. This action alters the cell's regulatory feedback mechanisms, resulting in a change in inflammatory pathway activity.

Suppressing the Inflammatory Mediator Cascade

The genomic action leads to the indirect functional suppression of the enzyme Phospholipase A2 (PLA2). By blocking PLA2 (via the up-regulated protein Lipocortin-1), the drug prevents the release of Arachidonic Acid, an essential precursor to physiological mediators like Prostaglandins and Leukotrienes. This blockade constrains a central step in the inflammatory cascade, resulting in a physiological reduction of tissue-level inflammatory signaling.

Modulating Local Immune and Vascular Responses

At the tissue level, the drug's mechanism causes localized vasoconstriction—a narrowing of the small blood vessels. This effect physiologically limits the leakage of fluid and blood flow into the irritated tissue, thereby limiting the extent of vasodilation and associated tissue edema (fluid leakage). Simultaneously, the drug exerts a localized immunosuppressive effect by limiting the migration and proliferation of key immune cells into the local tissue.

Dosage and Administration Information

How to Use U-Closone (Clobetasol Propionate): Official Administration Guidelines

This section outlines the official, labeled instructions for using U-Closone (clobetasol propionate), a high-potency topical corticosteroid, as defined by regulatory documents.

Administration Scope

Field Official Instruction
Route of Administration Topical/Dermatologic Use Only for creams, ointments, foams, and sprays. Not for oral, ophthalmic, or intravaginal use.
Standard Dosing Schedule Apply a thin layer to affected skin areas, typically twice daily (morning and evening).
Maximum Dosage Limit The total dosage must not exceed 50 grams (g) per week for most topical 0.05% formulations.

Procedural and Time Constraints

Field Official Instruction
Course Duration Limit Treatment should be limited to two consecutive weeks for most general dermatoses. Therapy should be discontinued when control is achieved.
Special Technique Apply the medication and rub it in gently and completely. Wash hands well after each application.
Occlusion Restriction Do not use with occlusive dressings (bandages or wraps) unless specifically directed by a healthcare provider.
Age-Group Rules Pediatric patients under 12 years of age are not generally recommended to use most topical 0.05% formulations.

Protocol Summary

The use protocol for U-Closone is structured around strict limitations on both time and amount to control systemic exposure. Patients must adhere to the maximum duration of two weeks and the maximum weekly dose of 50 grams. The required technique involves gentle application without the use of occlusive materials.

Recent Clinical Evidence

Research evidence / Overview of studies for U-Closone

U-Closone for Mild-to-Moderate Plaque Psoriasis

Research into U-Closone for treating mild-to-moderate plaque psoriasis primarily includes studies where participants were randomly assigned to receive either U-Closone or a different treatment, such as an inactive cream (placebo) or another established medication. These types of studies, known as randomized controlled trials (RCTs), are generally considered a way to explore treatment outcomes.

Findings from these key studies suggest a connection to observed changes in the signs and symptoms of mild-to-moderate plaque psoriasis. For many participants, the studies reported differences in measurements of skin symptoms like redness, thickness, and scaling compared to placebo. The degree of change, however, varied among the studies and among individual participants.

While the existing research offers initial information on what was explored in research with U-Closone in a general adult population with this type of psoriasis, there are still areas where evidence is limited. For example, long-term studies exploring outcomes in participants assigned to receive U-Closone consistently over a period much longer than a few months are less common. Also, fewer studies have focused on specific groups, such as children or older adults.

U-Closone for Mild-to-Moderate Atopic Dermatitis (Eczema)

The evidence base for U-Closone in the treatment of mild-to-moderate atopic dermatitis, also known as eczema, comes mainly from similar well-designed studies, where participants with this skin condition were randomly assigned to treatment groups. These studies focused on assessing how U-Closone affected common eczema symptoms, such as itching, skin inflammation, and overall skin appearance.

In several studies, measurements showed lower scores for symptoms in participants assigned to U-Closone compared to those assigned to a placebo. Specifically, some studies reported lower scores in measurements for inflammation and itching. The research, however, did not show that every participant benefited equally, and in some studies, the differences in outcomes between U-Closone and other comparators were mixed or not entirely clear.

A significant gap in the current evidence is a consistent body of research focused specifically on the research outcomes observed for infants and very young children assigned to U-Closone with this condition. The overall research pattern is heavily focused on adults and older children. Furthermore, studies directly comparing U-Closone against all other currently available treatments for eczema are also somewhat limited.

How should U-Closone be stored and disposed of?

How to Store and Dispose of U-Closone

The storage of U-Closone (Clobetasone Butyrate) must comply with regulatory conditions to maintain stability.

Storage Requirements

The medicine must be stored at a temperature not above 25 C and should be protected from light. It is mandatory to keep U-Closone out of the sight and reach of children and store it in its original package.

Stability and Handling

The product must not be used after the expiry date and, for certain formulations, should be discarded three months after first opening. A critical handling warning instructs users not to smoke or go near naked flames due to the fire hazard from contact with fabrics.

Disposal

Do not throw away this medicine via wastewater or household trash. Unused or expired U-Closone must be disposed of by returning it to a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagMalaysia

Equivalent of U-Closone found in:

A-Z Index: